3M Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 3/6
3M hat ein Gesamteigenkapital von $3.0B und eine Gesamtverschuldung von $12.6B, wodurch sich der Verschuldungsgrad auf 417.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $34.9B bzw. $31.9B. 3M Das EBIT des Unternehmens beträgt $5.1B, so dass der Zinsdeckungsgrad 7.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $5.3B.
Wichtige Informationen
417.67%
Verhältnis von Schulden zu Eigenkapital
US$12.55b
Verschuldung
| Zinsdeckungsgrad | 7.4x |
| Bargeld | US$5.30b |
| Eigenkapital | US$3.01b |
| Gesamtverbindlichkeiten | US$31.92b |
| Gesamtvermögen | US$34.92b |
Jüngste Berichte zur Finanzlage
Keine Aktualisierungen
Recent updates
Seeking Alpha • Jul 21
3M: The Turnaround Is Real, But Already Priced In
Summary 3M Company remains a Hold as valuation reached its fair value, even when taking into account the strong Q2 performance and guidance boost. 3M delivered 5.4% sales growth, 12% EPS growth in H1, and raised 2026 EPS guidance to $8.80–$8.95. Litigation liabilities and macro/geopolitical risks continue to weigh on 3M's risk-reward profile. AI/data center exposure and portfolio optimization offer long-term growth, but current risk-reward is unattractive. Read the full article on Seeking Alpha
Narrative-Update • Jul 20
MMM: PFAS Lawsuits Will Continue To Cap Upside Despite Improving Demand
Analysts have adjusted their fair value estimate for 3M slightly lower to about $121.62. This reflects a modestly higher discount rate alongside marginally stronger assumptions for revenue growth, profit margins, and a lower future P/E, informed by recent price target changes that highlight both optimism around improving industrial demand and ongoing concerns about execution and legacy risks.
Narrative-Update • Jul 06
MMM: Transformation And Legal Progress Will Support Future Re Rating
Analysts have trimmed their fair value estimate for 3M from $222.65 to $209.00. This reflects updated assumptions around discount rates, profit margins, and longer running concerns such as persistent PFAS liabilities and questions about the pace of the company's innovation recovery.
Narrative-Update • Jun 22
MMM: Future Margin Execution Faces PFAS Legal Risks After Solventum Spin
Analysts have trimmed their price expectations for 3M, with the updated fair value estimate moving from about $175.03 to $170.97, as recent research has highlighted concerns around execution risks in reigniting growth and ongoing PFAS liabilities, even as margin assumptions improved slightly. Analyst Commentary Recent Street research on 3M points to a mixed setup, with analysts split between concerns around execution and liabilities and some recognition that management has pulled meaningful levers through the ongoing transformation and portfolio moves such as the Solventum spin.Narrative-Update • Jun 06
MMM: PFAS Lawsuit And Overhang Will Constrain Future Upside Potential
Analysts have adjusted their view on 3M, with the implied fair value price target moving from about $125.70 to around $127.90. This reflects updated assumptions on revenue growth, profit margins, and future P/E following the Solventum spin and mixed recent price target changes across the Street.Narrative-Update • May 23
MMM: Margin Execution And Cash Returns Will Support Future Re Rating
Analysts have trimmed their 3M price target by about $1, reflecting slightly lower fair value estimates even as updated models factor in a reduced discount rate, modestly higher revenue growth, a small uptick in projected profit margins, and a somewhat lower future P/E assumption. Analyst Commentary Recent Street research around 3M and its healthcare spin-off Solventum gives you a mixed but generally constructive picture, with attention on how the separation could reshape both companies' earnings profiles and valuation frameworks.Narrative-Update • May 03
MMM: Future Margin Execution And Buybacks Will Support Turnaround Prospects
Analysts have adjusted the 3M price target slightly lower to reflect a new fair value near $175, as recent target cuts from several firms and one smaller increase from Wells Fargo suggest a more cautious view on profit margins, while revenue growth assumptions and future P/E expectations remain steady to slightly higher. Analyst Commentary Recent Street research reflects a more mixed stance on 3M, with several firms trimming price targets and one lifting its target, all clustering around a fair value in the mid US$170s.Narrative-Update • Apr 18
MMM: Execution On Margin Efficiency And Buybacks Will Support Future Re Rating
Analysts have trimmed their 3M fair value estimate by about $2 to $223.59, reflecting slightly lower profit margin assumptions that are only partly balanced by a modestly higher revenue growth outlook and a marginally richer future P/E multiple. Analyst Commentary Recent Street research on 3M reflects a mix of cautious revisions and selective optimism, with several firms adjusting price targets both higher and lower in response to updated assumptions.Narrative-Update • Apr 04
MMM: Operational Discipline And Legal Resolution Will Support Future Re Rating
Analysts have reduced the updated price target on 3M by about $1 to $225.94. This reflects a combination of recent target cuts and increases across firms, along with slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E.Narrative-Update • Mar 21
MMM: Operational Progress And Legal Overhang Resolution Will Support Future Re Rating
The analyst price target for 3M has been adjusted by a few dollars, reflecting mixed but generally constructive updates from recent research. Some firms raised their targets by $2 to $5, while others trimmed theirs by $6 to $8, based on refreshed views of growth, profitability, and valuation assumptions.Narrative-Update • Mar 06
MMM: Digital And Legal Progress Will Support Future Re Rating
The analyst price target for 3M has edged higher by about $1.50, as analysts weighed mixed target moves from major firms alongside slightly updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent Street research on 3M has been mixed, with some firms trimming their price targets while others raised theirs.Narrative-Update • Feb 20
MMM: Digital Execution And Slightly Higher Fair Value Will Support Re Rating
The analyst price target for 3M has shifted slightly higher, with our fair value estimate moving from $223.00 to about $225.67 as analysts factor in updated growth and margin assumptions, along with mixed target revisions across major firms. Analyst Commentary Recent Street research on 3M shows a split view, with several bullish analysts lifting price targets and others trimming expectations or downgrading the stock.Narrative-Update • Feb 05
MMM: Turnaround Prospects Will Be Tested By PFAS Litigation And Mixed Street Expectations
The analyst price target on 3M has been revised slightly higher to about $177 from $174, as analysts adjust their models for small changes in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions following a mix of recent target increases and cuts across major firms. Analyst Commentary Recent Street research on 3M has been mixed, with several firms adjusting their price targets in both directions and one major downgrade.Narrative-Update • Jan 22
MMM: New Digital Tools And Higher P E Multiple Will Support Re Rating
Analysts have nudged their valuation view on 3M higher, with the updated fair value estimate moving from $212 to $223 as they reassess the stock's longer term earnings power and apply a slightly richer future P/E multiple, despite mixed recent price target changes across the Street. Analyst Commentary Recent Street research on 3M has been mixed, with some firms trimming targets or ratings and others lifting their valuation marks.Narrative-Update • Jan 07
MMM: Reset Expectations And New Products Will Support Higher Margins
Analysts have raised their fair value estimate for 3M to $212 from $187, citing expectations for higher profit margins, a slightly lower discount rate, and supportive Street research that highlights Q3 execution, new product traction, and reset expectations across multiple firms. Analyst Commentary Recent Street research around 3M clusters around a more constructive setup following Q3, with several bullish analysts revisiting their models on the back of reset expectations, new product traction, and updated legal and macro assumptions.Narrative-Update • Dec 24
MMM: PFAS Litigation Will Ultimately Cap Upside Despite Turnaround Progress
Analysts have raised their price target on 3M, lifting fair value by about $12 per share to roughly $126 as they grow more confident in the company’s improving organic growth, margin expansion, and turnaround initiatives, despite ongoing PFAS litigation risks. Analyst Commentary Recent Street research reflects a more balanced, but still risk aware, view on 3M as estimates reset and execution on the turnaround improves.Narrative-Update • Dec 10
MMM: Turnaround Progress Will Face Ongoing PFAS Litigation And Portfolio Reshaping Risks
Our fair value estimate for 3M has been trimmed slightly to $174.25 from $174.94 as analysts balance higher price targets and improving expectations for new product driven growth and management's turnaround progress against persistent PFAS litigation risk. Analyst Commentary Street research remains divided on 3M, with recent notes highlighting improving execution and product driven growth, offset by continued concern around PFAS liabilities and mixed end market demand.Narrative-Update • Nov 26
MMM: Shares Will Balance Turnaround Progress With Litigation and Asset Sale Uncertainty
Analysts have marginally raised their fair value estimate for 3M to $174.94, citing improved organic growth, ongoing new product introductions, and increased profit margin expectations following recent quarterly results. Analyst Commentary Recent analyst research has revealed a shifting perspective on 3M, as several experts adjust their outlooks based on the company’s latest earnings performance and ongoing strategic initiatives.Narrative-Update • Nov 06
MMM: Shares Will Balance Turnaround Progress With Ongoing Litigation and Portfolio Changes
Analysts have raised their fair value estimate for 3M to $174.31 from $167.81. This change reflects improved organic growth prospects and progress on turnaround initiatives highlighted in recent research updates.Narrative-Update • Oct 22
Analysts Divided on 3M as Fair Value Rises Amid New Initiatives and Persistent Risks
3M's fair value estimate has increased by $5.00 to $167.81 as analysts cite modest operating outperformance and positive momentum from new product initiatives, despite some lingering concerns. Analyst Commentary Recent updates from Street research highlight diverging analyst sentiment regarding 3M's valuation trajectory and execution on strategic initiatives.Narrative-Update • Oct 08
New Product Launches And Efficiency Gains Will Boost Future Value
Narrative Update: 3M Analyst Price Target Revision Analysts have increased their price target for 3M to $162.81 from $161.63, citing improved full-year guidance prospects and renewed interest as a short-term buy idea. Analyst Commentary Recent commentary from Street research highlights both optimistic and cautious stances regarding 3M’s near-term prospects.Seeking Alpha • Mar 11
3M: Multiple Expansion Amidst Turnaround Success
Summary 3M has shown signs of a turnaround with a doubling stock price since October 2023, but operational top line growth remains modest, justifying a "hold" rating. The company expects modest organic revenue growth of 2-3% in 2025, driven by innovations and new product launches, but analysts are less optimistic. Current valuation is high with a forward P/E ratio above the five-year median, limiting upside potential amid risks like trade disputes and economic slowdowns. Read the full article on Seeking AlphaSeeking Alpha • Feb 07
3M: More Upside Ahead - But Wait For A Moderate Retracement
Summary MMM's reversal is already here, thanks to the SOLV divestiture bringing forth a more focused portfolio and healthier balance sheet. This is on top of the resolution of its legal headwinds, as management also pursues insurance recovery and $340M already completed. The management has driven new growth opportunities through its legacy businesses and new product launches as well, despite certain market softness. These reasons are likely why the market has upgraded MMM's valuations and the investors have defended the stock's uptrend support line thus far. With double digit capital appreciation prospects, we are reiterating our Buy rating here with one caveat. We shall further discuss. Read the full article on Seeking AlphaSeeking Alpha • Jan 23
3M Is Structurally Shifting For Durable Growth
Summary 3M's focus on innovation and operational improvements under CEO Bill Brown may lead to significant top-line growth and margin expansion. Management is aiming to enhance supply chain efficiencies and increasing production launches while improving the firm's on-time, in-full deliveries. 3M has a substantial amount of inventory that may be worked down in the coming quarters, potentially acting as a tailwind for free cash flow generation in the coming years. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
Downgrading 3M Due To Persistent Litigation Risks And Stagnant Sales Growth
Summary I am downgrading 3M from hold to sell due to slow revenue growth, ongoing litigation risks, and inflated stock valuation despite recent gains. Revenue growth is expected to underpace inflation, driven by product line adjustments, declining European demand, and the healthcare spin-off. Despite settling some litigations, 3M faces significant pending lawsuits, posing substantial financial risks. Shares appear expensive when accounting for slow growth and litigation risks, with a fair value estimate of $86 per share, 34% below current trading. Read the full article on Seeking AlphaSeeking Alpha • Dec 30
One Of JPMorgan's Value Picks For 2025, 3M Could Have A Bright Year Ahead
Summary JPMorgan highlights 3M Company as a key investment idea for 2025, despite ongoing legal challenges and growth issues, leading to my Hold rating. 3M's diverse operations span Safety & Industrial, Transportation & Electronics, Consumer, and Healthcare, with a strong focus on innovation and high-margin products. The company reported 1% organic growth and an 18% rise in adjusted EPS for Q3 2024, showcasing operational efficiency and cost management. With a healthy 23% margin and $1.5 billion free cash flow, MMM balances rewarding shareholders with investing in growth initiatives. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
3M: Seems A Bit Too Expensive Considering The Slow Growth
Summary Earlier this year, CEO William Brown said 3M's products are aging. Now and in the near future, it seems like the company is focussing on new products and research. It seems like the uncertainty-creating lawsuits are now largely settled, but the costs will weigh on the company for several years to come. Nevertheless, 3M has a strong financial position and rewards its shareholders with dividends and buybacks, but I'm waiting because I believe it is slightly too expensive. Read the full article on Seeking AlphaAnalyse der Finanzlage
Kurzfristige Verbindlichkeiten: MMMDie kurzfristigen Aktiva des Unternehmens ($14.1B) übersteigen seine kurzfristigen Passiva ($11.4B).
Langfristige Verbindlichkeiten: MMMDie kurzfristigen Vermögenswerte des Unternehmens ($14.1B) decken seine langfristigen Verbindlichkeiten ($20.5B) nicht.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: MMMDie Nettoverschuldung im Verhältnis zum Eigenkapital (241.2%) wird als hoch angesehen.
Schulden abbauen: MMMDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 125.7% auf 417.7% gestiegen.
Schuldendeckung: MMMDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (39%).
Zinsdeckung: MMMDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (7.4x Coverage) gut gedeckt.
Bilanz
Entdecken Sie finanziell stabile Unternehmen
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/04 09:41 |
| Aktienkurs zum Tagesende | 2026/08/03 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
3M Company wird von 29 Analysten beobachtet. 14 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Eade | Argus Research Company |
| Julian Mitchell | Barclays |
| Robert Cornell | Barclays |